TCR T-cell therapy (NCI/Kite Pharma)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameTCR T-cell therapy (NCI/Kite Pharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionHuman leukocyte antigen modulators

TargetsHuman leukocyte antigen

Therapy Area/IndicationsLung NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKite Pharma Inc National Cancer Institute

Active IndicationsN/A

Inactive IndicationsLung NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A